CCR9 antagonism: Potential in the treatment of Inflammatory Bowel Disease

Clinical and Experimental Gastroenterology

Volumn 8, Issue , 2015, Pages 119-130

  Wendt, Emily ^a   Keshav, Satish ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

CC chemokine receptor 9; CCL25; CCX282 B; Crohn s disease; GSK10605786; Traficet EN; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALPHA INTEGRIN; ALPHA4 INTEGRIN; AZATHIOPRINE; BETA INTEGRIN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 5; KI 67 ANTIGEN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; TACROLIMUS; TRANSCRIPTION FACTOR GATA 3; UNINDEXED DRUG; USTEKINUMAB; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB; VERCIRNON;

BONE MARROW SUPPRESSION; CALCIUM TRANSPORT; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COLON RESECTION; CROHN DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; LYMPHOMA; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE ILEUS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84936953701     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S48305     Document Type: Review

References (97)

1. Loftus EV JR. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.
3. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-2078.
4. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation - therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47-89.
5. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621.
6. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122(4):854-866.
7. Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol. 2007;21(9):583-587.
8. Oberhuber G, Stangl PC, Vogelsang H, Schober E, Herbst F, Gasche C. Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch. 2000;437(3):293-297.
9. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008;57(12):1682-1689.
10. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol. 1996;157(3):1261-1270.
11. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150(3):823-832.
12. Fais S, Capobianchi MR, Pallone F, et al. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut. 1991;32(4):403-407.
13. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78(1): 127-131.
14. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112(4):1169-1178.
15. Okazawa A, Kanai T, Watanabe M, et al. Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement. Am J Gastroenterol.2002;97(12):3108-3117.
16. + T cells in immunity to viruses. Nat Rev Immunol. 2012;12(2):136-148.
17. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113(10):1490-1497.
18. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129(2):550-564.
19. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002;8(6):567-573.
20. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70.
21. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454-467.
22. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461-1463.
23. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-753.
24. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ. 2008;336(7652):1062-1066.
25. Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18(12):2203-2208.
26. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-368.
27. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721.
28. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528.
29. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993;7(4):369-383.
30. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590-599.
31. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59(9):1200-1206.
32. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15(11):1699-1708.
33. Saibeni S, Virgilio T, D'Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008;40(10):814-820.
34. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther. 2013;37(9):855-866.
35. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
36. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther. 2004;20 Suppl 4:88-92.
37. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909-1915.
38. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev. 2013;252(1):164-182.
39. + T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011;121(10):4170-4179.
40. Fell JM, Walker-Smith JA, Spencer J, MacDonald TT. The distribution of dividing T cells throughout the intestinal wall in inflammatory bowel disease (IBD). Clin Exp Immunol. 1996;104(2):280-285.
41. Feng T, Wang L, Schoeb TR, Elson CO, Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med. 2010;207(6):1321-1332.
42. + regulatory T cells. J Immunol. 2003;170(8):3939-3943.
43. Dutra RC, Claudino RF, Bento AF, et al. Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PloS One. 2011;6(11):e27122.
44. Weber C, Alon R, Moser B, Springer TA. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. J Cell Biol. 1996;134(4):1063-1073.
45. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-689.
46. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341(24):1817-1828.
47. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400(6746):776-780.
48. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21(4):527-538.
49. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int. 2002;52(5-6):367-374.
50. Connor EM, Eppihimer MJ, Morise Z, Granger DN, Grisham MB. Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. J Leukoc Biol. 1999;65(3): 349-355.
51. Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106(4):748-761.
52. Agace W. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Lett. 2010;128(1):21-23.
53. Vicari AP, Figueroa DJ, Hedrick JA, et al. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997;7(2):291-301.
54. Zabel BA, Agace WW, Campbell JJ, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med. 1999;190(9):1241-1256.
55. Kunkel EJ, Campbell JJ, Haraldsen G, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med. 2000;192(5):761-768.
56. Svensson M, Marsal J, Ericsson A, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest. 2002;110(8):1113-1121.
57. Stenstad H, Svensson M, Cucak H, Kotarsky K, Agace WW. Differential homing mechanisms regulate regionalized effector CD8alphabeta+ T cell accumulation within the small intestine. Proc Natl Acad Sci U S A. 2007;104(24):10122-10127.
58. Rivera-Nieves J, Ho J, Bamias G, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology. 2006;131(5):1518-1529.
59. Wermers JD, McNamee EN, Wurbel MA, Jedlicka P, Rivera-Nieves J. The chemokine receptor CCR9 is required for the T cell-mediated regulation of chronic ileitis in mice. Gastroenterology. 2011;140(5): 1526-1535.
60. Wurbel MA, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PloS One. 2011;6(1):e16442.
61. Papadakis KA, Prehn J, Nelson V, et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol. 2000;165(9):5069-5076.
62. Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 2001;121(2):246-254.
63. Yu CR, Peden KW, Zaitseva MB, Golding H, Farber JM. CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand. J Immunol. 2000;164(3):1293-1305.
64. Papadakis KA, Landers C, Prehn J, et al. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol. 2003;171(1):159-165.
65. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ. Evidence for NK cell subsets based on chemokine receptor expression. J Immunol. 2006;177(11):7833-7840.
66. Wendland M, Czeloth N, Mach N, et al. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci U S A. 2007;104(15):6347-6352.
67. Hadeiba H, Lahl K, Edalati A, et al. Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity. 2012;36(3):438-450.
68. + macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology. 2012;142(2):366-376.
69. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115(Pt 3):455-465.
70. Wurbel MA, Malissen M, Guy-Grand D, et al. Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood. 2001;98(9):2626-2632.
71. Wurbel MA, Malissen M, Guy-Grand D, Malissen B, Campbell JJ. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol. 2007;178(12):7598-7606.
72. + T cells display CCR9-dependent and -independent homing to the small intestine. Blood. 2006;107(9):3447-3454.
73. Saruta M, Yu QT, Avanesyan A, Fleshner PR, Targan SR, Papadakis KA. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007;178(5):3293-3300.
74. + gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200(11):1511-1517.
75. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000;87(11):1480-1493.
76. Engel DR, Koscielny A, Wehner S, et al. T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract. Nat Med. 2010;16(12):1407-1413.
77. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25(6):727-739.
78. Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590-1599.
79. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010;335(1):61-69.
80. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10(3):387-398.
81. ChemoCentryx. A study to evaluate the efficacy and safety of CCX282-B in subjects with moderate to severe Crohn's disease. Available from: http://clinicaltrials.gov/show/NCT00306215. NLM Identifier: NCT00306215. Accessed August 2, 2014.
82. Keshav S, Vaňásek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PloS One. 2013;8(3):e60094.
83. GlaxoSmithKline. A study to investigate the efficacy and safety of GSK1605786A in the treatment of subjects with moderately-to-severely active Crohn's disease (SHIELD-1). Available from: http://clinicaltrials.gov/show/NCT01277666. NLM Identifier: NCT01277666. Accessed August 2, 2014.
84. GlaxoSmithKline. GSK1605786A in the maintenance of remission in subjects with Crohn's disease (SHIELD-2). Available from: http://clinicaltrials.gov/show/NCT01316939. NLM Identifier: NCT01316939. Accessed August 2, 2014.
85. GlaxoSmithKline. Open-label extension study of GSK1605786A (SHIELD-3). Available from: http://clinicaltrials.gov/show/NCT01318993. NLM Identifier: NCT01318993. Accessed August 2, 2014.
86. GlaxoSmithKline. An active treatment study to induce clinical response and/or remission with GSK1605786A in subjects with Crohn's disease (SHIELD-4). Available from: http://clinicaltrials.gov/show/NCT01536418. NLM Identifier: NCT01536418. Accessed August 2, 2014.
87. Eberhardson M, Marits P, Jones M, et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol. 2013;149(1):73-82.
88. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology. 2001;33(5):1065-1072.
89. ChemoCentryx. Safety and activity study of an oral medication to treat moderate to severe Crohn's disease. Available from: http://clinicaltrials.gov/show/NCT00102921. NLM Identifier: NCT00102921. Accessed August 2, 2014.
90. + B cells. Clin Exp Immunol. 2005;141(2):279-287.
91. Kunkel EJ, Kim CH, Lazarus NH, et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest. 2003;111(7):1001-1010.
92. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541-546.
93. Reuter BK, Pizarro TT. Mechanisms of tight junction dysregulation in the SAMP1/YitFc model of Crohn's disease-like ileitis. Ann N Y Acad Sci. 2009;1165:301-307.
94. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology. 2008;134(7):2025-2035.
95. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5(11):1461-1471.
96. Mizukami T, Kanai T, Mikami Y, et al. CCR9(+) macrophages are required for eradication of peritoneal bacterial infections and prevention of polymicrobial sepsis. Immunol Lett. 2012;147(1-2):75-79.
97. Wang C, Kang SG, Hogenesch H, Love PE, Kim CH. Retinoic acid determines the precise tissue tropism of inflammatory Th17 cells in the intestine. J Immunol. 2010;184(10):5519-5526.